Discontinued — last reported Q3 '21
Royalty — Potential milestone payment receipts
Neurocrine Biosciences Royalty — Potential milestone payment receipts remained flat by 0.0% to $366M in Q3 2021 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests a robust pipeline of upcoming clinical or regulatory catalysts, whereas a decrease may reflect the completion of milestones or the termination of development programs.
Detailed definition
This metric quantifies the future cash inflows contingent upon the achievement of specific clinical, regulatory, or comm...
Peer comparison
Often disclosed in the 'Collaborations' or 'Licensing' footnotes of financial statements as 'Contingent Consideration' or 'Milestone Payments' by peers in the life sciences sector.
nbix_segment_royalty_potential_milestone_payment_receiptsHistorical Data
| Q2 '21 | Q3 '21 | |
|---|---|---|
| Value | $366M | $366M |
| QoQ Change | — | +0.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's royalty — potential milestone payment receipts?
- Neurocrine Biosciences (NBIX) reported royalty — potential milestone payment receipts of $366M in Q3 2021.
- What does royalty — potential milestone payment receipts mean?
- The total value of future payments expected if specific development or commercial goals are met under partnership agreements.